AG
NVET

Advisor Group’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Advisor Group’s Portfolio NVET Stock Details NVET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-90
Closed – – 5029
2017
Q1 		$0 Hold
90
– – ﹤0.01% 4914
2016
Q4 		$0 Hold
90
– – ﹤0.01% 4757
2016
Q3 		$0 Hold
90
– – ﹤0.01% 4747
2016
Q2 		$0 Buy
+90
New +$313 ﹤0.01% 4618

Other funds holding NVET

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KAM
Kassirer Asset Management Toronto, Ontario, Canada $4.07M AUM 49.71% 1-Year Est. Return
HCMT
Highland Capital Management (Texas) Dallas, Texas $39M AUM
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
GP
GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return
SMC
S. Muoio & Co New York $75.7M AUM 42.51% 1-Year Est. Return

Advisor Group's NVET Position: Q2 2017 in Review

Advisor Group sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q2 2017, closing a stake of 90 shares.

Advisor Group first reported a position in NVET in Q2 2016 and held it in 4 quarters. The position peaked at $0 in Q1 2017. 20 funds tracked by Wall St. Rank hold NVET as of Q2 2017.

  • Advisor Group reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q2 2017 after selling out during the quarter.
  • Advisor Group sold 90 Nexvet Biopharma plc Ordinary Shares shares in Q2 2017.
  • Advisor Group first reported a position in Nexvet Biopharma plc Ordinary Shares in Q2 2016 and held it in 4 quarters.
  • Advisor Group's Nexvet Biopharma plc Ordinary Shares position peaked at $0 in Q1 2017.
  • 20 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q2 2017.

Based on Advisor Group's 13F filing for Q2 2017, filed 11 Aug 2017.